The AACR Trailblazer Cancer Research Grant Program, which was launched at the Annual Meeting Opening Ceremony, will award $15 million over three years. It is designed for early-stage and mid-career investigators to support meritorious and promising cancer research. “AACR has been a proud funder of… Read More
DDW Editor Megan Thomas speaks to Paul Peter Tak, President and CEO of Candel Therapeutics, about the company's cancer data and its development of next-generation viral immunotherapies targeting solid tumours. MT: Please provide a brief overview of Candel’s pipeline? PT: Candel’s clinical stage pipeline is built on two distinct multimodal… Read More
Advances in cancer therapy have produced powerful treatments that can greatly improve survival – but can also trigger fearsome side-effects. Notably, CAR-T cell therapies can cause cytokine release syndrome (CRS). Managing CRS is an area that is becoming increasingly important to Big Pharma, reports DDW’s Megan Thomas. CAR-T cell cancer… Read More
Mosaic Therapeutics has in-licensed two clinical-stage oncology programmes from Astex Pharmaceuticals, a subsidiary of Otsuka Pharmaceutical. Mosaic has identified combinations incorporating the licensed products and their targets and the agreement gives Mosaic the exclusive rights to develop those combination products for patients for whom there are no, or limited, treatment… Read More
The largest study to date of the most common form of testicular cancer has uncovered a possible link between disease risk and variations in the genes controlling cell shape and movement. The study reveals new insights into how rare genetic variants may contribute to susceptibility – laying… Read More
AstraZeneca, Tempus AI and Pathos AI have entered a multi-year, strategic collaboration to build a multimodal foundation model in oncology. The model will be used to gather biological and clinical insights, discover novel drug targets, and develop therapeutics for the broader oncology community. Upon completion, the model will be shared… Read More
Data from the Friends of Cancer Research’s (Friends’) ctMoniTR Project, recently published in Clinical Cancer Research (CCR), demonstrate a strong association between changes in levels of circulating tumour DNA (ctDNA) and treatment outcomes. This offers the potential for integration of ctDNA analysis in therapeutic development programmes, and clinical cancer… Read More
Medicus Pharma has announced plans to extend its SKNJCT-003 Phase II clinical study for the treatment of nodular basal cell carcinoma (BCC). The Institutional Review Board (IRB) has approved the increase in the number of patients from 60 to 90. The trial will expand into… Read More
March Biosciences (March Bio) announced that the first patient has been dosed in its Phase II clinical trial evaluating MB-105, a first-in-class CD5-targeted CAR-T cell therapy for patients with relapsed or refractory CD5-positive T-cell lymphoma. “This represents a significant milestone in advancing MB-105 as a potential treatment… Read More
Aulos Bioscience has dosed its first patient with a combination of AU-007, the anti-PD-1 antibody nivolumab and low-dose, subcutaneous aldesleukin in a Phase II expansion cohort focused on second-line treatment of melanoma. The new cohort forms part of the company’s Phase I/II clinical trial of AU-007… Read More
Candel Therapeutics’ CAN-2409 has demonstrated a median overall survival (mOS) of 24.5 months in a Phase IIa clinical trial in patients with stage III/IV non-small cell lung cancer (NSCLC). The 46 evaluable patients, who are nonresponsive to immune checkpoint inhibitor (ICI) treatment, received two courses of CAN-2409. Read More
Scientists at the Cancer Research Manchester Institute have created a new model of Lung Squamous Cell Carcinoma (LUSC) to study the development, activity, and vulnerabilities of the disease. In the UK, around 80 to 85% of lung cancers are non-small cell lung cancer, of which squamous cell… Read More
The 2025 AACR-Margaret Foti Award for Leadership and Extraordinary Achievements in Cancer Research will be presented to William Hait, Fellow of the AACR Academy, during the AACR Annual Meeting 2025. Hait served as the Global Head of Janssen Research and Development and was the executive vice president,… Read More
Cancer Research Horizons has announced a collaboration with Histofy to develop tools that predict how colorectal cancer patients respond to different treatment options using the multi-modal S:CORT dataset. As part of the collaboration, Histofy will use digital pathology images, as well as clinical and molecular data, from the S:CORT dataset… Read More
Scientists at The Institute of Cancer Research, London, are collaborating with life sciences company QBiotics to understand the molecular and cellular mechanisms of a potential new cancer drug. The collaborative team will study the effects of tigilanol tiglate – a naturally occurring small molecule derived from the… Read More
Cancer Research UK and partners have committed £5.5 ($7.1) million in funding to form a world-leading research team tasked with making personalised medicine a reality for people with bowel cancer. The CRC-STARS initiative will bring together over 40 research experts from across the UK, Spain, Italy and… Read More
